CAMBRIDGE, Mass., April 12, 2018 /PRNewswire/ -- TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today that new preclinical data on its TRuC™ platform and its lead solid tumor program TC-210 will be presented at the American Association for Cancer Research (AACR) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, IL.
The poster presentations will discuss rationales and mechanisms for the company's HLA-independent TRuC™-T cells and provide additional updates for TC-210, the company's lead program targeting mesothelin-positive solid tumors. TC-210 is advancing into the clinic later this year for solid tumor indications including ovarian, mesothelioma, cholangiocarcinoma, pancreatic and lung cancers. Abstracts are available on the AACR conference website at http://www.aacr.org.
Abstract #3584
Advertisement
The poster presentations will discuss rationales and mechanisms for the company's HLA-independent TRuC™-T cells and provide additional updates for TC-210, the company's lead program targeting mesothelin-positive solid tumors. TC-210 is advancing into the clinic later this year for solid tumor indications including ovarian, mesothelioma, cholangiocarcinoma, pancreatic and lung cancers. Abstracts are available on the AACR conference website at http://www.aacr.org.
Advertisement
Abstract #3584
- Title: Characterization of a novel class of engineered (TCR) fusion constructs (TRuC™s) aimed to treat solid tumors
- Session Title: Category: Clinical Research, Title: Adoptive Cell Therapy 3
- Date & Time: Tuesday, April 17, 2018 8:00 AM - 12:00 PM CDT
- Location: McCormick Place South, Exhibit Hall A, Poster Section 24
- Title: Preclinical evaluation of mesothelin-specific T cell receptor (TCR) fusion constructs (TRuC™s) utilizing the signaling power of the complete TCR complex: A new opportunity for solid tumor therapy
- Session Title: Category: Clinical Research, Title: Adoptive Cell Therapy 3
- Date & Time: Tuesday, April 17, 2018 8:00 AM - 12:00 PM CDT
- Location: McCormick Place South, Exhibit Hall A, Poster Section 24
View original content:http://www.prnewswire.com/news-releases/tcr2-therapeutics-to-present-new-preclinical-data-at-the-american-association-for-cancer-research-aacr-2018-annual-meeting-300628614.html
SOURCE TCR2 Therapeutics